
REV. MÉD. ROSARIO 91: 92-99, 2025
REVISTA MÉDICA DE ROSARIO98
9. Notario R, Borda N, Deserti S, Gambandé T. Infecciones
entéricas por Campylobacter jejuni en Rosario. Medicina
(Buenos Aires) 45:654-658, 1985.
10. Cox JM, Brook MD, Woolcock JB. Sensitivity of Austra-
lian isolates of Salmonella Enteritidis to nitrofurantoin and
furazolidone. Vet Microbiol. 49(3-4):305-308,1996.
11. Antunez P, Machado J, Peixe L. Illegal use of nitrofurans
in food animals: contribution to human salmonellosis? Clin
Microbiol infect. 12(11):1047-1049, 2006.
12. Yates J. Traveler´s diarrhea. Am Fam Physician.
71(11):2095-2100, 2005.
13. Notario R, Borda N, Gajardo T y col. Infección intestinal
por Campylobacter jejuni resistente al ácido nalidíxico. In-
fectol & Microbiol Clin. 7:38-41, 1995.
14. Notario R, Borda N, Gambandé T y col. Quinolone resis-
tant Campylobacter jejuni strains isolated from humans and
from poultry. Medicina (B Aires). 71(4):331-335, 2011.
15. Hines J, Nachamkin I. Eective use of the clinical micro-
biology laboratory for diagnosing diarrheal diseases. Clin
Infect Dis 23:1292-1301,1996.
16. Bartolomé Porro JM, Vecino López R, Rubio Murillo M.
Diarrea aguda. Protoc diagn ter pediatr.1:99-108, 2023.
17. Gendrel D, Cohen R; European Society for Pediatric Infec-
tious Diseases; European Society for Gastroenterology, Hepa-
tology and Nutrition. Bacterial diarrheas and antibiotics:
European recommendations. Arch Pediatr. 15(2):S93-S96,
2008.
18. Yoh M, Frimpong EK, Voravuthikunchai SP y col. Eects
of subinhibitory concentrations of antimicrobial agents (qui-
nolones and macrolide) on the production of verotoxin by
enterohemorrhagic Escherichia coli O157:H7. Can J Mi-
crobiol 54:732-739, 1999.
19. Amran M, Fujii J, Kolling G y col. Proposal for eective
treatment of Shiga toxin-producing Escherichia coli infec-
tion in mice. Microb Pathog 65:57-62, 2013.
20. Zhang Q, Donohue-Rolfe A, Krautz-Peterson G y col.
Gnotobiotic piglet infection model for evaluating the safe use
of antibiotics against Escherichia coli O157:H7 infection.
Journal Infect Dis. 199:486-493, 2009.
21. Bielaszewska M, Idelevich EA, Zhang W y col. Eects of
antibiotics on Shiga toxin2 producction and bacteriopha-
ge induction by epidemic Escherichia coli O104:H4 strain.
Antimic Agents Chemother. 56:3277-3282, 2012.
22. Nitschke M, Sayk F, Härtel C y col. Association between
azithromycin therapy and duration of bacterial shedding
among patients with Shiga toxin-producing enteroaggrega-
tive Escherichia coli O104:H4. JAMA 307: 1046-1052,
2012.
23. Kakoullis L, Papachristodoulou E, Chra P, Panos G. Shi-
ga toxin-induced haemolytic uraemic syndrome and the role
of antibiotics: a global overview. J Infect 79:75-94, 2019.
24. Tajiri H, Nishi J, Ushijima K y col. A role for fosfmycin
treatment in childrn for prevention of haemolytic-uraemic
syndrome accompanying Shiga toxin-producing Escheri-
chia coli infection. Int J Antimicrob Agents. 46:586-589,
2015.
25. Launders N, Byrne L, Jenkins C y col. Disease severity of
Shiga toxin-producing E. coli O157 and factors inuen-
cing the development of typical haemolytic uraemic síndro-
me: a retrospective cohort study, 2009-2012. BMJ Open.
6:e009933, 2016.
26. Agger M, Scheutz F, Villumsen S y col. Antibiotic
treatment of verocytotoxin-producing Escherichia coli
(VTEC) infection: a systematic review AND proposal. J
Antimicrob Chemother. 70:2440-2446, 2015.
27. Kahn WA, Seas C, Dhar U y col. Treatment of shige-
llosis: Comparison of azithromycin and cciprooxacin. A
double blind, randomized, controlled trial. Ann Intern
Med.126:697-703, 1997.
28. Martín-Pozo A, Arana D, Fuentes M, Alós JI. Sensibili-
dad a azitromicina y otros antibióticos en aislados recientes
de Salmonela, Shigella y Yersinia. Enferm Infecc Micro-
biol Clin. 32(6):369-371, 2014.
29. Crump J, Sjölund-Karlsson M, Gordon M, Parry C.
Epidemiology, Clinical Presentation, Laboratory Diagnosis,
Antimicrobial Resistance, and Antimicrobial Management
of Invasive Salmonella infections. Clin Microbiol Rev.
28(4):901-937, 2015.
30. Smith KE,Besser JM,Hedberg CW y col. Quinolone-re-
sistant Campylobacter jejuni infections in Minnesota, 1992-
1998. Investigation Team. N Engl J Med. 340(20):1525-
1532,1999.
31. Jost C, Bidet P, Carrère T y col. Susceptibility of entero-
haemorrhagic Escherichia coli to azithromycin in France
and análisis of resistance mechanisms. J Antimicrob Che-
mother. 71(5):1183-1187,2016.
32. Wei B, Cha SY, Kang M y col. Antimicrobial proles and
molecular typing of Campylobacter jejuni and Campylobac-
ter coli isolates from ducks in South Korea. Appl Environ
Microbiol. 80(24):7604-7610, 2014.
33. Borda N, Gambandé T, Notario R. Dos casos de enteri-
tis com bacteriemia por Campylobacter jejuni. Medicina
(Buenos Aires) 66:450-452,2006.
34. Gonzáles-Abad MJ, Alonso-Sanz M. Incidencia y sensibili-
dad de Campylobacter jejuni en pacientes pediátricos: implica-
ción en bacteriemia. Rev Esp Quimioter 26:92-96, 2013.